secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeoVax Labs, Inc. (GOVX)
CIK:        0000832489
Form:       8-K
Filed at:   2023-05-05T23:59:59+00:00
Accession:  0001437749-23-012679
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeoVax Q1 2023 net loss $4.04M ($0.15/share); cash $23.85M; clinical progress on CM04S1 and Gedeptin
--------------------------------------------------------------------------------

- Net loss $4,037,916 ($0.15/share) vs $2,427,515 ($0.34/share) in Q1 2022; R&D expense $2.82M (+112% YoY); G&A $1.45M (+23%).
- Cash $23.85M at March 31, 2023, down $3.76M from Dec 31, 2022; no revenue reported.
- Phase 2 CM04S1 COVID-19 vaccine trial data presented at World Vaccine Congress shows immunogenicity in immunocompromised patients.
- Gedeptin Phase 1/2 cancer trial expanded to three NCI-designated centers; enrollment expected to complete in Q2 2023.
- Expanded NIH license rights to include orthopoxviruses (Mpox, smallpox) for MVA-based vaccine development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/832489/000143774923012679/0001437749-23-012679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/832489/000143774923012679/govx20230503_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-012679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer